Table 2 Baseline characteristics of exercise and non-exercise groups

Age (yr)

68.6 ± 8.4

66.3 ± 9.0

Height (cm)

170.8 ± 8.5

171.6 ± 7.8

Weight (kg)

85.0 ± 17.8

77.0 ± 12.1

BMI (kg·m⁻²)

28.5 ± 4.7

26.1 ± 4.0

ADT duration (mo)

14.6 ± 15.4

12.7 ± 11.6

Gleason score

7.4 ± 0.9

7.6 ± 0.9

Time since diagnosis (yr)

4.7 ± 5.1

4.7 ± 4.9

Testosterone (ng·dl⁻¹)

25.0 ± 7.3

6.3 ± 37.4

PSA (ng·ml^− 1)

2.1 ± 4.4

0.8 ± 2.4

Number of comorbidities^a

2.6 ± 1.9

1.7 ± 1.4

Number of medications

3.0 ± 2.5

4.1 ± 3.3

Anti-androgen, n (%)

8 (50%)

12 (63.1%)

Metastatic disease, n (%)

10 (62.5%)

9 (47.3%)

Metastases type, n (%)

 Nodal metastases

2 (12.5%)

2 (10.5%)

 Bone metastases

6 (37.5%)

7 (36.8%)

 Other metastases sites^b

2 (12.5%)

0 (0%)

Ethnicity, n (%)

 White

8 (50.0%)

11 (57.9%)

 African American

2 (12.5%)

1 (10.5%)

 Asian/Pacific Islander

4 (25.0%)

5 (26.3%)

 Hispanic

2 (12.5%)

2 (10.5%)

Previous radiation, n (%)

8 (53.3%)

10 (52.6%)

Previous surgery, n (%)

12 (75.0%)

12 (63.1%)

Previous chemotherapy, n (%)

2 (12.5%)

2 (10.5%)

Caloric intake (kcal·day⁻¹)

1903.0 ± 629.4

1688.1 ± 376.3

Protein intake (g·kg^− 1·day^− 1)

1.0 ± 0.4

1.1 ± 0.5

Total physical activity (min·wk.^− 1)^c

654.8 ± 789.5

999.1 ± 910.8

 Moderate activity (min·wk.^− 1)

221.4 ±  210.3

397.3 ±  429.2

 Vigorous activity (min·wk.^− 1)

144.6 ±  323.8

129.2 ±  151.5